NASDAQ:NXL Nexalin Technology (NXL) Stock Price, News & Analysis → 348 million Americans lives to END as we know it? (From The Oxford Club) (Ad) Free NXL Stock Alerts $1.21 -0.09 (-6.92%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$1.21▼$1.3050-Day Range$0.31▼$2.8752-Week Range$0.25▼$3.40Volume40,879 shsAverage Volume588,441 shsMarket Capitalization$9.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Nexalin Technology alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Nexalin Technology Stock (NASDAQ:NXL)Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.Read More NXL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXL Stock News HeadlinesApril 25, 2024 | finanznachrichten.deNexalin Technology, Inc.: Nexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsApril 25, 2024 | globenewswire.comNexalin Technology Regains Compliance with Nasdaq Continued Listing RequirementsMay 9, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 12, 2024 | investing.comNexalin Technology advances in mental health treatmentApril 10, 2024 | globenewswire.comNexalin Technology CEO Provides Letter to ShareholdersApril 6, 2024 | stockhouse.comNexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity(TM), a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceApril 4, 2024 | globenewswire.comNexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation DeviceApril 2, 2024 | proactiveinvestors.comNexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransMay 9, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 2, 2024 | globenewswire.comNexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory BoardMarch 30, 2024 | finance.yahoo.comNexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)March 28, 2024 | globenewswire.comNexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San DiegoMarch 14, 2024 | finance.yahoo.comNexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s TechnologyMarch 14, 2024 | globenewswire.comNexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's TechnologyMarch 13, 2024 | globenewswire.comNexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”March 6, 2024 | globenewswire.comNexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic InsomniaFebruary 8, 2024 | finance.yahoo.comNexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation DeviceJanuary 23, 2024 | finance.yahoo.comNexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) SystemJanuary 17, 2024 | morningstar.comNexalin Technology Inc NXLJanuary 11, 2024 | stockhouse.comNexalin Technology Unveils Next-Generation HALO(TM) ClarityJanuary 11, 2024 | finance.yahoo.comNexalin Technology Unveils Next-Generation HALO™ ClarityDecember 18, 2023 | finance.yahoo.comNexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant DepressionOctober 16, 2023 | finance.yahoo.comNexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain StructuresSeptember 14, 2023 | barrons.comNexalin Technology Inc.August 7, 2023 | finance.yahoo.comNexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related SymptomsAugust 3, 2023 | finance.yahoo.comNexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern TimeJuly 27, 2023 | finance.yahoo.comNexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government AgenciesSee More Headlines Receive NXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nexalin Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:NXL CUSIPN/A CIK1527352 Webwww.nexalin.com Phone832-260-0222FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,650,000.00 Net Margins-4,185.46% Pretax Margin-4,197.82% Return on Equity-122.57% Return on Assets-97.00% Debt Debt-to-Equity RatioN/A Current Ratio8.07 Quick Ratio7.70 Sales & Book Value Annual Sales$110,748.00 Price / Sales81.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book2.81Miscellaneous Outstanding Shares7,437,000Free Float5,378,000Market Cap$9.00 million OptionableNot Optionable Beta5.80 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Marilyn Elson (Age 71)Controller Comp: $382.72kMr. Mark White (Age 62)President, CEO, CFO & Director Comp: $191.29kMr. John Patrick ClaudeCo-Founder and Director of Engineering & DevelopmentDr. David Owens M.D. (Age 63)Chief Medical Officer & Director Mr. Michael Nketiah (Age 48)Senior Vice-President of Quality, Regulatory & Clinical Affairs Comp: $251.6kKey CompetitorsSolunaNASDAQ:SLNHLendwayNASDAQ:LDWYShapewaysNYSE:SHPWUpexiNASDAQ:UPXIPintec TechnologyNASDAQ:PTView All Competitors NXL Stock Analysis - Frequently Asked Questions How have NXL shares performed in 2024? Nexalin Technology's stock was trading at $0.4048 at the beginning of 2024. Since then, NXL shares have increased by 198.9% and is now trading at $1.21. View the best growth stocks for 2024 here. Are investors shorting Nexalin Technology? Nexalin Technology saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 327,200 shares, an increase of 243.7% from the March 31st total of 95,200 shares. Based on an average daily volume of 786,600 shares, the days-to-cover ratio is currently 0.4 days. Currently, 5.6% of the shares of the company are sold short. View Nexalin Technology's Short Interest. When did Nexalin Technology IPO? Nexalin Technology (NXL) raised $10 million in an initial public offering (IPO) on Friday, September 16th 2022. The company issued 2,315,000 shares at a price of $4.15 per share. How do I buy shares of Nexalin Technology? Shares of NXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NXL) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nexalin Technology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.